HighTower Advisors
QNCX icon

HighTower Advisors’s Quince Therapeutics QNCX Stock Holding History

HighTower Advisors’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,643
Closed -$1.1M – 3908
2025
Q4 		$1.1M Buy
1,643
+100
+6% +$50.3K ﹤0.01% 2050
2025
Q3 		$503K Hold
1,543
– – ﹤0.01% 2615
2025
Q2 		$509K Sell
1,543
-175
-10% -$40K ﹤0.01% 2506
2025
Q1 		$457K Buy
1,718
+10
+0.6% +$3.05K ﹤0.01% 2538
2024
Q4 		$639K Hold
1,708
– – ﹤0.01% 2283
2024
Q3 		$273K Hold
1,708
– – ﹤0.01% 2884
2024
Q2 		$251K Buy
+1,708
New +$309K ﹤0.01% 2866

Other funds holding QNCX

WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.5B AUM 75.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

HighTower Advisors's QNCX Position: Q1 2026 in Review

HighTower Advisors sold out of Quince Therapeutics (QNCX) in Q1 2026, closing a stake of 1,643 shares — an estimated $1.1M sold.

HighTower Advisors first reported a position in QNCX in Q2 2024 and held it in 7 quarters. The position peaked at $1.1M in Q4 2025. 43 funds tracked by Wall St. Rank hold QNCX as of Q1 2026.

  • HighTower Advisors reported no remaining Quince Therapeutics position as of Q1 2026 after selling out during the quarter.
  • HighTower Advisors sold 1,643 Quince Therapeutics shares in Q1 2026, an estimated $1.1M.
  • HighTower Advisors first reported a position in Quince Therapeutics in Q2 2024 and held it in 7 quarters.
  • HighTower Advisors's Quince Therapeutics position peaked at $1.1M in Q4 2025.
  • 43 funds tracked by Wall St. Rank held Quince Therapeutics as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.